Human iPS cell technologies are attracting a lot of interest in the nonclinical test for drug development for several years. Notably, it was demonstrated that proarrhythmia risk assessment using human iPS cell-derived cardiomyocytes and multi electrode array (MEA) system showed high clinical predictability. In the proarrhythmia risk assessment, it was well known that field potential duration (FPD) was a surrogate marker for QT duration and wave changes which showed early afterdepolarization (EAD) were observed by application of hERG channel blockers in MEA system. Arrhythmia risk were classified by FPD prolongation and occurrence of EAD. On the other hand, heart failure induced by anti-cancer drugs is an important issue in safety pharmacology. Many in vitro contractility platforms are introduced from some companies. In vivo echo and catheters assess whole heart contractility function. Parameters acquired by in vitro contractility platforms are absolutely different from parameters acquired by in vivo data. It is difficult to compare between in vivo data and in vitro data and to evaluate usefulness of in vitro platforms. In this symposium, I would like to discuss about evaluation of correlation between in vivo contractility data and in vitro contractility data.